87 Kodiak Sciences Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) Year Ended December 31, 2023 2022 2021 Operating expenses Research and development $ 206,298 $ 267,591 $ 217,340 General and administrative 71,023 73,788 49,711 Total operating expenses 277,321 341,379 267,051 Loss from operations (277,321) (341,379) (267,051) Interest income 16,733 7,071 298 Interest expense (13) (18) (47) Other income (expense), net 110 503 (190) Net loss $ (260,491) $ (333,823) $ (266,990) Net loss per common share, basic and diluted $ (4.97) $ (6.39) $ (5.16) Weighted-average shares of common stock outstanding used in computing net loss per common share, basic and diluted 52,414,256 52,249,620 51,788,918 Other comprehensive income (loss) Change in unrealized gains (losses) related to availabl a e-for-sale debt securities, net of tax 1,307 (1,307) (53) Total other comprehensive income (loss) 1,307 (1,307) (53) Comprehensive loss $ (259,184) $ (335,130) $ (267,043) The accompanying notes are an integral part of these consolidated financial statements.